SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare shines on receiving approval from USFDA for Irinotecan HCL Injection

01 Jan 2019 Evaluate

Shilpa Medicare is currently trading at Rs. 398.40, up by 14.35 points or 3.74% from its previous closing of Rs. 384.05 on the BSE.

The scrip opened at Rs. 400.00 and has touched a high and low of Rs. 401.30 and Rs. 396.25 respectively. So far 860 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 637.00 on 12-Jan-2018 and a 52 week low of Rs. 357.95 on 23-Jul-2018.

Last one week high and low of the scrip stood at Rs. 401.30 and Rs. 371.00 respectively. The current market cap of the company is Rs. 3131.04 crore.

The promoters holding in the company stood at 53.80%, while Institutions and Non-Institutions held 32.16% and 14.04% respectively.

Shilpa Medicare has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL Injection USP, 40 mg/2mL and 100 mg/5mL (20mg/mL) Single Dose Vials. Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum.

According to IQVIA MAT Q2 2018 data, the US market for Irinotecan HCL approximately $18 million

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine
Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×